FJY Stock Chart & Stats
€0.02
<€0.01(18.75%)
At close: 4:00 PM EST
€0.02
<€0.01(18.75%)
Day’s Range― - ―
52-Week Range<€0.01 - €0.02
Previous CloseN/A
Volume10.00K
Average Volume (3M)14.84K
Market Cap
€4.19M
Enterprise Value€5.85M
Total Cash (Recent Filing)€1.71M
Total Debt (Recent Filing)€2.52M
Price to Earnings (P/E)―
Beta0.73
Next Earnings
Mar 02, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding611,654,100
10 Day Avg. Volume14,844
30 Day Avg. Volume14,844
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)3.46
Price to Sales (P/S)1.09
P/FCF Ratio4.98
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)<0.01
Revenue Forecast (FY)€8.73M
Bulls Say, Bears Say
Bulls Say
2026 Revenue ReboundThe strong 2026 revenue rebound shows that the business can recover after periods of contraction and regain commercial traction. If this improvement persists, a larger revenue base could support operating leverage, better resource utilization, and a stronger foundation for future earnings growth.
Positive 2026 Cash FlowPositive operating and free cash flow in the latest year is an important improvement because it indicates the business generated cash despite continuing accounting losses. Sustained cash generation would reduce reliance on external funding and provide greater flexibility to support ongoing operations.
Narrower Net LossA substantially narrower net loss suggests that the recent revenue recovery is beginning to improve the company’s earnings trajectory. Although profitability has not yet been achieved, continued progress could reduce cash requirements and move the business closer to a sustainable operating model.
Bears Say
Persistent Operating LossesPersistent net, EBIT, and EBITDA losses show that the company has not yet established a sustainable profit engine. Continued losses can consume financial resources, constrain reinvestment, and make future performance dependent on successfully converting the recent revenue rebound into durable margins.
Elevated LeverageThe sharp increase in debt-to-equity reflects a materially smaller equity cushion and leaves creditors and shareholders with less balance-sheet protection. For a biotechnology company with recurring losses, elevated leverage can restrict financial flexibility and increase the consequences of operating setbacks.
Volatile Revenue And Cash GenerationLarge swings in revenue and free cash flow indicate that recent improvement may not yet represent a stable underlying trend. If revenue normalizes or costs rise, cash burn could re-emerge, making planning more difficult and weakening the durability of the company’s financial recovery.
Acrux News
FJY FAQ
What was Acrux Limited’s price range in the past 12 months?
Acrux Limited lowest stock price was <€0.01 and its highest was €0.02 in the past 12 months.
What is Acrux Limited’s market cap?
Acrux Limited’s market cap is €4.19M.
When is Acrux Limited’s upcoming earnings report date?
Acrux Limited’s upcoming earnings report date is Mar 02, 2027 which is in 140 days.
How were Acrux Limited’s earnings last quarter?
Acrux Limited released its earnings results on Aug 21, 2026. The company reported -€0.001 earnings per share for the quarter.
Is Acrux Limited overvalued?
According to Wall Street analysts Acrux Limited’s price is currently Overvalued.
Does Acrux Limited pay dividends?
Acrux Limited does not currently pay dividends.
What is Acrux Limited’s EPS estimate?
Acrux Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Acrux Limited have?
Acrux Limited has 611,654,100 shares outstanding.
What happened to Acrux Limited’s price movement after its last earnings report?
Acrux Limited reported an EPS of -€0.001 in its last earnings report. Following the earnings report the stock price went down -21.429%.
Which hedge fund is a major shareholder of Acrux Limited?
Currently, no hedge funds are holding shares in DE:FJY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Acrux Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Neutral
DE:FJY Sentiment 50%
Sector Average 66%
Sector Average 66%
Insider Transactions
Bought Shares
Worth €93.0K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Fundamentals
Return on Equity
-45.29%
Trailing 12-Months
Asset Growth
-12.39%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Acrux Limited
Acrux Limited and its associated entities specialize in the development and commercialization of generic and topically applied pharmaceutical products. Their global operations span Australia, Europe, the United States, and various other international markets. The company provides a comprehensive range of testosterone therapies for adult males experiencing insufficient or absent testosterone levels, including oral and buccal tablets, subcutaneous pellets, transdermal patches, injectable formulations, and topical gels. Furthermore, Acrux offers estradiol sprays, specifically marketed under the brand names Evamist and Lenzetto, to women for the management of hot flashes associated with menopause. Established in 1998, the firm's headquarters are located in West Melbourne, Australia.
Technical Analysis
Clinuvel Pharmaceuticals
―
Starpharma Holdings Limited
―
Tissue Repair Ltd
―
Regeneus Ltd.
―
Botanix Pharmaceuticals Limited
―